Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers
利用技术激活造血细胞移植幸存者及其初级保健提供者的皮肤癌筛查
基本信息
- 批准号:10595099
- 负责人:
- 金额:$ 79.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAgeCancer BurdenCancer DetectionCancer SurvivorCancer SurvivorshipCardiovascular systemCaringCellular PhoneClinicalCoupledDermatologicDermatologistDermatologyDetectionDiagnosisE-learningEarly DiagnosisEarly treatmentEducationEducational process of instructingEndocrineEnrollmentEnsureExposure toFaceFutureGeneral PopulationHealth PromotionHematologic NeoplasmsHematological DiseaseHematologyHigh-Risk CancerIndividualKnowledgeLate EffectsLesionLong-Term CareLong-Term SurvivorsMalignant NeoplasmsMeasuresMedicalMorbidity - disease rateNeoplasmsOncologyParticipantPatientsPatternPhysiciansPopulationPreventive carePrimary CarePrimary Care PhysicianPrintingProviderQuality of lifeRadiation exposureRandomizedRecurrenceReportingResearch PriorityRiskRisk FactorsScreening for Skin CancerSelf-ExaminationSkinSkin CancerSkin CarcinomaSurvival RateSurvivorsTechnologyTestingTherapeutic immunosuppressionTimeTransplant RecipientsTreatment-Related CancerUnited States National Institutes of HealthWhole-Body Irradiationadvanced diseasebehavioral outcomecancer diagnosisclinically relevantcomparative effectiveness studyconditioningcostcost effectivedigitalexperiencefollow-upgraft vs host diseasehealth related quality of lifehematopoietic cell transplantationhigh riskimplementation scienceimprovedinnovationmelanomamortalitymultidisciplinaryprevention practiceprimary care providerprimary care settingprogramsresponsescreeningskillssurvivorshiptransplant centerstransplant survivor
项目摘要
SUMMARY/ABSTRACT
Hematopoietic cell transplantation (HCT) is a curative option for a growing number of patients with hematologic
diseases and malignancies. However, HCT-related factors, such as total body irradiation used for conditioning,
graft-versus-host disease, and prolonged exposure to immunosuppressive therapy, result in very high risk for
subsequent skin cancers. Compared with the general population, HCT survivors are also more likely to develop
skin cancers at a younger age, have advanced disease at presentation, and experience multiple recurrences.
Despite this high burden, less than 20% of long-term HCT survivors report being examined for skin cancer, even
though >90% were seen by their primary care physician (PCPs) in the prior year. In HCT survivors, skin cancers
develop at a time when their follow-up care has largely transitioned from oncology care to the primary care
setting, emphasizing the need to develop innovative strategies that 1) provide HCT survivors with the skills to
conduct effective skin self-examinations, and prompt action from their providers when worrisome lesions are
found; 2) engage PCPs in HCT risk-based screening for skin cancer; and 3) ensure rapid access to dermatologic
exams. Advances in technology, including widespread availability of cell phones and teledermoscopy (remote
expert assessment of a photographed lesion) offer promising opportunities to improve early detection and
treatment of skin cancer. We propose a comparative effectiveness study that will examine the impact of patient
activation and education (PAE), alone or in combination with physician-tailored strategies, on clinically
meaningful behavioral outcomes. We will enroll 720 HCT survivors at a large, diverse HCT center to:
1) Determine the impact of PAE alone or with physician activation (PAE+Phys) on skin cancer screening and
prevention practices at 12 months; and 2) Among PCPs of HCT survivors, determine the impact of a
teledermoscopy e-learning program compared with provision of print materials for identifying suspect lesions.
We hypothesize that compared to PAE, patients randomized to PAE+Phys will report higher rates of thorough
self- and provider skin exam, shorter time to referral of suspicious lesions, and improved quality of life; compared
to print materials alone, physicians randomized to teledermoscopy e-learning will have greater recognition of
suspect lesions and more appropriate, cost-effective referral patterns. Our multi-disciplinary team will: 1)
establish the efficacy of PAE, and the relative benefit of physician activation; 2) inform the practice of skin cancer
screening using innovative mobile strategies that are readily applicable in the clinical setting; and 3) identify
facilitators of and barriers to appropriate delivery of survivorship-focused preventive care for long-term HCT
survivors. Information obtained from the current study can be used to develop strategies for management of
other late effects (e.g. cardiovascular, endocrine) in HCT survivors in the primary care setting, and to improve
skin cancer screening in other high-risk (e.g. radiation-exposed) cancer survivor populations.
摘要/摘要
造血细胞移植(HCT)是越来越多血液病患者的一种治疗选择
疾病和恶性肿瘤。然而,HCT 相关因素,例如用于调理的全身照射,
移植物抗宿主病和长期接受免疫抑制治疗会导致非常高的风险
随后的皮肤癌。与一般人群相比,HCT 幸存者也更有可能发生
皮肤癌发病年龄较轻,就诊时已处于晚期,并且会多次复发。
尽管负担如此沉重,但只有不到 20% 的长期 HCT 幸存者报告接受了皮肤癌检查,即使
尽管超过 90% 的人是在上一年去看初级保健医生 (PCP) 的。在 HCT 幸存者中,皮肤癌
在他们的后续护理基本上从肿瘤护理过渡到初级护理的时候发展
背景,强调需要制定创新战略,1)为 HCT 幸存者提供以下技能:
进行有效的皮肤自我检查,并在出现令人担忧的病变时立即采取行动
成立; 2) 让 PCP 参与基于 HCT 风险的皮肤癌筛查; 3) 确保快速获得皮肤科治疗
考试。技术进步,包括手机和远程皮肤镜检查(远程
对拍摄的病变进行专家评估)为改善早期发现和治疗提供了有希望的机会
治疗皮肤癌。我们提出了一项比较有效性研究,该研究将检验患者的影响
激活和教育(PAE),单独或与医生定制的策略相结合,在临床上
有意义的行为结果。我们将在一个大型、多元化的 HCT 中心招募 720 名 HCT 幸存者,以便:
1) 确定 PAE 单独使用或与医生激活 (PAE+Phys) 对皮肤癌筛查的影响
12个月时的预防措施; 2) 在 HCT 幸存者的 PCP 中,确定
远程皮肤镜电子学习计划与提供印刷材料进行比较,以识别可疑病变。
我们假设与 PAE 相比,随机接受 PAE+Phys 的患者将报告更高的彻底治疗率
自我和提供者皮肤检查,缩短转诊可疑病变的时间,并提高生活质量;比较的
仅打印材料,随机参加远程皮肤镜电子学习的医生将获得更大的认可
可疑病变和更合适、更具成本效益的转诊模式。我们的多学科团队将:1)
确定 PAE 的功效以及医生激活的相对益处; 2)告知皮肤癌的实践
使用易于应用于临床环境的创新移动策略进行筛查; 3) 识别
适当提供以幸存者为中心的长期 HCT 预防性护理的促进因素和障碍
幸存者。从当前研究中获得的信息可用于制定管理策略
初级保健机构中 HCT 幸存者的其他后期影响(例如心血管、内分泌),并改善
对其他高风险(例如暴露于辐射的)癌症幸存者人群进行皮肤癌筛查。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Saro Armenian其他文献
Saro Armenian的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Saro Armenian', 18)}}的其他基金
Remote monitoring of cardiac function in childhood cancer survivors
远程监测儿童癌症幸存者的心脏功能
- 批准号:
10274206 - 财政年份:2021
- 资助金额:
$ 79.82万 - 项目类别:
Remote monitoring of cardiac function in childhood cancer survivors
远程监测儿童癌症幸存者的心脏功能
- 批准号:
10456314 - 财政年份:2021
- 资助金额:
$ 79.82万 - 项目类别:
Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers
利用技术激活造血细胞移植幸存者及其初级保健提供者的皮肤癌筛查
- 批准号:
10375440 - 财政年份:2020
- 资助金额:
$ 79.82万 - 项目类别:
Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation
造血细胞移植幸存者的心血管储备能力
- 批准号:
10092215 - 财政年份:2020
- 资助金额:
$ 79.82万 - 项目类别:
Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation
造血细胞移植幸存者的心血管储备能力
- 批准号:
10558477 - 财政年份:2020
- 资助金额:
$ 79.82万 - 项目类别:
Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation
造血细胞移植幸存者的心血管储备能力
- 批准号:
10369583 - 财政年份:2020
- 资助金额:
$ 79.82万 - 项目类别:
Reducing risk of Anthracycline-related heart failure after childhood cancer
降低儿童癌症后与蒽环类药物相关的心力衰竭的风险
- 批准号:
9103021 - 财政年份:2015
- 资助金额:
$ 79.82万 - 项目类别:
Reducing risk of Anthracycline-related heart failure after childhood cancer
降低儿童癌症后与蒽环类药物相关的心力衰竭的风险
- 批准号:
8941193 - 财政年份:2015
- 资助金额:
$ 79.82万 - 项目类别:
Anthraycline-related cardiotoxicity in long-term survivors of lymphoma
淋巴瘤长期幸存者与蒽环类药物相关的心脏毒性
- 批准号:
8569676 - 财政年份:2013
- 资助金额:
$ 79.82万 - 项目类别:
Anthraycline-related cardiotoxicity in long-term survivors of lymphoma
淋巴瘤长期幸存者与蒽环类药物相关的心脏毒性
- 批准号:
8689987 - 财政年份:2013
- 资助金额:
$ 79.82万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 79.82万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 79.82万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 79.82万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 79.82万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 79.82万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 79.82万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 79.82万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 79.82万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 79.82万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 79.82万 - 项目类别:
Directed Grant














{{item.name}}会员




